Authors: Pegram, MD Lopez, A Konecny, G Slamon, DJ

Citation: Md. Pegram et al., Trastuzumab and chemotherapeutics: Drug interactions and synergies, SEMIN ONCOL, 27(6), 2000, pp. 21-25

Authors: Aguilar, Z Akita, RW Finn, RS Ramos, BL Pegram, MD Kabbinavar, FF Pietras, RJ Pisacane, P Sliwkowski, MX Slamon, DJ

Citation: Z. Aguilar et al., Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells, ONCOGENE, 18(44), 1999, pp. 6050-6062

Authors: Pegram, MD Slamon, DJ

Citation: Md. Pegram et Dj. Slamon, Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity, SEMIN ONCOL, 26(4), 1999, pp. 89-95

Authors: Lopez, AM Pegram, MD Slamon, DJ Landaw, EM

Citation: Am. Lopez et al., A model-based approach for assessing in vivo combination therapy interactions, P NAS US, 96(23), 1999, pp. 13023-13028

Authors: Pietras, RJ Pegram, MD

Citation: Rj. Pietras et Md. Pegram, Oncogene activation and breast cancer progression, CONT ENDOC, 11, 1999, pp. 133-153

Authors: Pegram, MD Pauletti, G Slamon, DJ

Citation: Md. Pegram et al., HER-2/neu as a predictive marker of response to breast cancer therapy, BREAST CANC, 52(1-3), 1998, pp. 65-77